Shanghai Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Clin Nutr. 2022 Aug;41(8):1787-1797. doi: 10.1016/j.clnu.2022.06.030. Epub 2022 Jun 30.
BACKGROUND & AIMS: Recent evidence suggests that gut microbiota may represent an important factor to affect the development of obesity and obesity-related diseases. Although several randomized controlled trials (RCTs) have explored the ability of Lactobacillus to improve metabolic parameters in adults who are overweight or obese, their findings have been inconsistent and require further analysis. Therefore, this systematic review and meta-analysis aimed to determine the ability of Lactobacillus supplementation to improve glycemic control, the lipid profile, and blood pressure in adults who are overweight or obese.
Seven electronic databases and two trial registers were searched up to April 2022 to identify eligible RCTs evaluating the effects of Lactobacillus supplementation in overweight or obese adults. Mean differences (MDs) or standardized mean differences were pooled using a random-effects model.
Nine eligible RCTs with 598 participants were included. We found that Lactobacillus supplementation significantly reduced low-density lipoprotein cholesterol (MD -5.27 mg/dL; 95% confidence interval [CI] -8.28, -2.25; P = 0.0006) and total cholesterol (MD -4.84 mg/dL; 95% CI -8.29, -1.39; P = 0.006), particularly when taken in capsule, powder, or tablet form, for 12 weeks, as ≥1 × 10 colony forming units/day, or as part of a normal diet. Benefits of Lactobacillus on fasting plasma glucose were seen after 12 weeks of supplementation (MD -1.81 mg/dL; 95% CI -3.08, -0.54; P = 0.005) and on triglycerides when taking a normal diet (MD -14.14 mg/dL; 95% CI -24.38, -3.91; P = 0.007). Lactobacillus had only a short-term beneficial effect on fasting plasma insulin and blood pressure and no significant beneficial effect on high-density lipoprotein cholesterol.
Lactobacillus supplementation has a beneficial effect on low-density lipoprotein cholesterol and total cholesterol in adults who are overweight or obese, and also on fasting plasma glucose and triglycerides under certain conditions. Therefore, Lactobacillus supplementation represents a promising approach in the management of obesity-related diseases.
最近的证据表明,肠道微生物群可能是影响肥胖及其相关疾病发展的重要因素。虽然几项随机对照试验(RCT)已经探索了乳酸菌改善超重或肥胖成年人代谢参数的能力,但他们的发现不一致,需要进一步分析。因此,本系统评价和荟萃分析旨在确定乳酸菌补充剂改善超重或肥胖成年人血糖控制、血脂谱和血压的能力。
截至 2022 年 4 月,我们检索了 7 个电子数据库和 2 个试验登记处,以确定评估乳酸菌补充剂对超重或肥胖成年人影响的合格 RCT。使用随机效应模型汇总均数差(MD)或标准化均数差。
纳入了 9 项合格 RCT,共 598 名参与者。我们发现,乳酸菌补充剂可显著降低低密度脂蛋白胆固醇(MD -5.27 mg/dL;95%置信区间 [CI] -8.28,-2.25;P = 0.0006)和总胆固醇(MD -4.84 mg/dL;95%CI -8.29,-1.39;P = 0.006),特别是在服用胶囊、粉末或片剂形式、每天摄入 ≥1×10 菌落形成单位、或作为正常饮食的一部分时,持续 12 周。在补充 12 周后,乳酸菌对空腹血糖的益处可见(MD -1.81 mg/dL;95%CI -3.08,-0.54;P = 0.005),在正常饮食时对甘油三酯的益处可见(MD -14.14 mg/dL;95%CI -24.38,-3.91;P = 0.007)。乳酸菌对空腹血浆胰岛素和血压只有短期的有益影响,对高密度脂蛋白胆固醇没有显著的有益影响。
乳酸菌补充剂对超重或肥胖成年人的低密度脂蛋白胆固醇和总胆固醇有有益影响,在某些条件下也对空腹血糖和甘油三酯有有益影响。因此,乳酸菌补充剂代表了肥胖相关疾病管理的一种有前途的方法。